EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel NUP98::ASH1L Gene Fusion in Acute Myeloid Leukemia Detected by Optical Genome Mapping

Marco Tembrink iD, Wanda Maria Gerding iD, Stefan Wieczorek, Thomas Mika, Roland Schroers iD, Huu Phuc Nguyen iD, Deepak Ben Vangala iD, Verena Nilius-Eliliwi iD

Cancers · 27.05.2023 · 15 (11) · 2942

DOI: 10.3390/cancers15112942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 27.05.2023. Verfasst von Marco Tembrink und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Ruhr-University Bochum, 44801 Bochum, Germany. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: InnovationsFoRUM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optical genome mapping (OGM) recently has demonstrated the potential to improve genetic diagnostics in acute myeloid leukemia (AML). In this study, OGM was utilized as a tool for the detection of genome-wide structural variants and disease monitoring. A previously unrecognized NUP98::ASH1L fusion was detected in an adult patient with secondary AML. OGM identified the fusion of NUP98 to Absent, Small, or Homeotic-Like Histone Lysine Methyltransferase (ASH1L) as result of a complex structural rearrangement between chromosomes 1 and 11. A pipeline for the measurement of rare structural variants (Rare Variant Pipeline, Bionano Genomics, San Diego, CA, USA) was used for detection. As NUP98 and other fusions are relevant for disease classification, this demonstrates the necessity for methods such as OGM for cytogenetic diagnostics in AML. Furthermore, other structural variants showed discordant variant allele frequencies at different time points over the course of the disease and treatment pressure, indicating clonal evolution. These results support OGM to be a valuable tool for primary diagnostics in AML as well as longitudinal testing for disease monitoring and deepening our understanding of genetically heterogenous diseases.

Schlagwörter

Stichwörter der Autor:innen

clonal evolutioncytogeneticsdisease monitoring: structural variantskaryotypingrare variant pipeline

Autor:innen und Institutionen

  • Department of Human Genetics, Ruhr-University Bochum, 44801 Bochum, Germany.
  • MVZ Dr. Eberhard & Partner Dortmund GbR (ÜBAG), 44137 Dortmund, Germany.
  • Department of Medicine, Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum, 44892 Bochum, Germany.

ORCID-Profile: Marco Tembrink, Wanda Maria Gerding, Roland Schroers, Huu Phuc Nguyen, Deepak Ben Vangala, Verena Nilius-Eliliwi

Förderung

  • InnovationsFoRUM

Zitieren

APA

Tembrink, M., Gerding, W. M., Wieczorek, S., Mika, T., Schroers, R., Nguyen, H. P., Vangala, D. B., & Nilius-Eliliwi, V. (2023). Novel NUP98::ASH1L Gene Fusion in Acute Myeloid Leukemia Detected by Optical Genome Mapping. Cancers, 15(11), 2942. https://doi.org/10.3390/cancers15112942

Vancouver

Tembrink M, Gerding WM, Wieczorek S, Mika T, Schroers R, Nguyen HP, et al. Novel NUP98::ASH1L Gene Fusion in Acute Myeloid Leukemia Detected by Optical Genome Mapping. Cancers. 2023;15(11):2942. doi:10.3390/cancers15112942

BibTeX
@article{Tembrink2023,
  author = {Tembrink, Marco and Gerding, Wanda Maria and Wieczorek, Stefan and Mika, Thomas and Schroers, Roland and Nguyen, Huu Phuc and Vangala, Deepak Ben and Nilius-Eliliwi, Verena},
  title = {Novel NUP98::ASH1L Gene Fusion in Acute Myeloid Leukemia Detected by Optical Genome Mapping},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {11},
  pages = {2942},
  doi = {10.3390/cancers15112942}
}
Kostenlos starten →